Special Issue "New Developments in Rheumatoid Arthritis"
Deadline for manuscript submissions: 31 July 2024 | Viewed by 220
Interests: rheumatoid arthritis; oncogenes; autoimmunity
Rheumatoid arthritis is a canonical autoimmune disease characterized by chronic inflammation in the joints and causes severe functional sequelae if untreated. The success of cytokine-targeting treatments has improved our understanding of the molecular pathways in RA and shifted the treatment goal from the palliative management of late consequences to early remission and the prevention of RA-related morbidity, but even more remains to be explored. A deeper understanding of RA pathogenesis is critical to solve the unmet needs.
Despite all that we have learned, many questions still remain unanswered. For example, what is the order of priority of cellular events in RA, and how can we trace these events in patients? How does autoimmunity transform into arthritis? How do the molecular events change during different clinical stages of the disease? How can we match the molecular events in RA pathology with the choice of anti-rheumatic drugs? Great strides have been made toward answering these and other important questions, but clear answers have yet to be found. The answers to these questions will provide some clues for the individualized treatment of RA.
The purpose of this Special Issue is to highlight recent findings regarding the molecular mechanisms of RA. This Special Issue will provide a broad scope of research, including original studies and reviews related to the specific interactions between the immune system and arthritis, genetics, and lifestyle-related risk factors, directly or indirectly affecting the pathogenesis and treatment outcome of the disease.
Prof. Dr. Maria Bokarewa
Dr. Alf Kastbom
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- rheumatoid arthritis
- risk factors